Gastroesophageal Adenocarcinoma Clinical Trial
Official title:
Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial) - a Phase Ib Feasibility Trial
This is a phase 1b prospective, single arm, open-label trial determining the efficacy and feasibility of using a ctDNA assay (test) result to help guide neoadjuvant chemotherapy in subjects with Stage IB, II or Stage III adenocarcinoma of the stomach or gastroesophageal junction (GEA).
Status | Not yet recruiting |
Enrollment | 20 |
Est. completion date | February 2026 |
Est. primary completion date | February 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Patients must have histologically or cytologically confirmed adenocarcinoma of the stomach or gastroesophageal junction (GEA). Other GE histologies which are treated per NCCN guidelines for neoadjuvant treatment are eligible. - Must have Stage IB, II or Stage III GEA eligible for (neo)adjuvant doublet or triplet chemotherapy for up to 6 months. - Must have baseline ctDNA positive assay (tested by Signatera MRD assay) prior to initiation of neoadjuvant chemotherapy. Patients who are otherwise eligible may start per protocol treatment if ctDNA result is not available at the time of initiation of systemic therapy. However, once the results is available, they can only remain on study if the ctDNA is positive. - Age = 18 years Because the safety or efficacy of neoadjuvant chemotherapy for LGEA has not been tested or established for patients <18 years of age, children are excluded from this study but will be eligible for future pediatric trials, if applicable. - Performance status: ECOG performance status =2 - Life expectancy of greater than 6 months - Adequate organ and marrow function as defined below: 1. leukocytes = 3,000/mcL 2. absolute neutrophil count = 1,500/mcL 3. platelets = 80,000/mcl 4. total bilirubin within normal institutional limits 5. AST(SGOT)/ALT(SPGT) = 5 X institutional upper limit of normal 6. creatinine <2 X ULN - Docetaxel can cause fetal harm and irinotecan is known to be teratogenic. Since these compounds are part of the treatment regimens, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days following completion of therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. 1. A female of child-bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria: 1. Has not undergone a hysterectomy or bilateral oophorectomy; or 2. Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months). - Ability to understand and the willingness to sign a written informed consent. 1. Both men and women and members of all races and ethnic groups are eligible for this trial. Non-English speaking, deaf, hard of hearing and illiterate individuals are eligible for this trial. Exclusion Criteria: - Patients may not be receiving any other investigational agents. - Patients with known metastases from GEA. - History of allergic reactions attributed to agents used in study. - Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. - History of another primary cancer which requires active treatment or is expected to require treatment within 12 months after enrollment. - Inability to comply with study and follow-up procedures as judged by the Investigator. - Patients who are pregnant or nursing due to the potential for congenital abnormalities and the potential of this regimen to harm nursing infants. |
Country | Name | City | State |
---|---|---|---|
United States | Chao Family Comprehensive Cancer Center, University | Orange | California |
Lead Sponsor | Collaborator |
---|---|
University of California, Irvine | Natera, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of completing per protocol treatment. | Percent of patients who will undergo attempt at curative intent resection. | Up to 3 years | |
Secondary | Percentage of patients completing gastrectomy. | Percent of patients completing gastrectomy | Up to 3 years | |
Secondary | Rate of negative ctDNA after completion of neoadjuvant treatment and within 8 weeks after surgery | Percent of patients with ctDNA clearance after neoadjuvant chemotherapy and after surgery (within 6-8 weeks) | 8 weeks | |
Secondary | Rate of R0 resection | R0 resection is defined as complete tumor removal with negative surgical margins. | Up to 3 years | |
Secondary | Rate of post-operative complication rate within 30 days after surgery | Up to 3 years | ||
Secondary | Percentage of Grade 3-5 Adverse Events | Toxicity and adverse events are based on the CTCAE (NCI Common Terminology Criteria for Adverse Events) Version 5.0. | Up to 3 years | |
Secondary | Relapse-free survival time | The lead time in ctDNA detection before clinical recurrence | Up to 3 years | |
Secondary | Rate of ctDNA positive patients at diagnosis | Percent of patients positive for ctDNA at diagnosis | Up to 3 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05977322 -
A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors.
|
Phase 1 | |
Completed |
NCT00073502 -
Phase II Study of Single Agent OSI-7904L in Patients With Gastric or Gastroesophageal (GEJ) Cancer
|
Phase 2 | |
Recruiting |
NCT04712721 -
Study of [68Ga]-FF58 in Patients With Selected Solid Tumors Expected to Overexpress αvβ3 and αvβ5 Integrins.
|
Early Phase 1 | |
Recruiting |
NCT05029882 -
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab
|
Phase 1 | |
Withdrawn |
NCT04602117 -
ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer
|
Phase 1 | |
Completed |
NCT03794128 -
A Study of Personalized Neoantigen Cancer Vaccines
|
||
Active, not recruiting |
NCT04021108 -
Phase II Study of Short Course FOLFOX Chemotherapy With Either Nivolumab or Nivolumab + Radiation in the First Line Treatment of Metastatic or Unresectable Gastroesophageal Cancers (BMS Protocol CA209-76L)
|
Phase 2 | |
Not yet recruiting |
NCT06445972 -
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
|
Phase 1/Phase 2 | |
Completed |
NCT01045421 -
MLN8237 in Adults With Nonhematological Malignancies, Followed by MLN8237 in Lung, Breast, Head and Neck or Gastroesophageal Malignancies
|
Phase 1/Phase 2 | |
Completed |
NCT03639714 -
A Study of a Personalized Neoantigen Cancer Vaccine
|
Phase 1/Phase 2 | |
Completed |
NCT01757171 -
Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma
|
Phase 2 | |
Recruiting |
NCT05152147 -
A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers
|
Phase 3 | |
Not yet recruiting |
NCT05986227 -
The Sequential Combination of FOLFOX and Toripalimab for Perioperative Immuno-Oncology Therapy of HER2-negative Adenocarcinoma of the Esophagogastric Junction (Siewert I/II):
|
Phase 1/Phase 2 | |
Terminated |
NCT01182610 -
Panitumumab, Paclitaxel, Carboplatin and 5FU in the Treatment of Potentially Resectable Gastroesophageal Adenocarcinoma
|
Phase 2 | |
Recruiting |
NCT06043427 -
Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma
|
Phase 2 |